Roth Capital Initiates Coverage on Neuralstem(NASDAQ:CUR). The shares have been rated Buy. The rating by Roth Capital was issued on Aug 29, 2016.
Neuralstem (CUR) shares turned negative on Thursdays trading session with the shares closing down -0.0194 points or -6.81% at a volume of 7,41,815. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.29. The peak price level was also seen at $0.29 while the days lowest was $0.26. Finally the shares closed at $0.2656. The 52-week high of the shares is $1.96 while the 52-week low is $0.19. According to the latest information available, the market cap of the company is $30 M.
Neuralstem(CUR) last announced its earnings results on Aug 12, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-0.04. Analysts had estimated an EPS of $-0.05.
Several Insider Transactions has been reported to the SEC. On Nov 16, 2015, Karl Johe (Chief Scientific Officer) sold 25,000 shares at $1.09 per share price.
Neuralstem Inc. (Neuralstem) is engaged in development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and its small molecule compounds. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from all areas of the developing human brain and spinal cord thus enabling the generation of physiologically relevant human neurons of all types. It has developed and patented a series of small molecule compounds. The Company is developing products using technology including Cell Therapy and Small Molecule Pharmaceutical Compounds. The Company has a wholly owned subsidiary Suzhou Sun-Now Biopharmaceutical Co. Ltd. in China. Its clinical programs include the NSI-566 and NSI-189.